|Mr. Stephan Jackman||CEO & Director||225k||N/A||1976|
|Mr. Henry C.W. Nisser Esq.||Exec. VP, Gen. Counsel & Director||50k||N/A||1969|
|Mr. Kenneth S. Cragun CPA||Sr. VP of Fin.||100k||N/A||1961|
|Mr. Milton Charles Ault III||Founder & Chairman Emeritus||N/A||N/A||1970|
|Ms. Lien T. Escalona||Chief Financial Officer||N/A||N/A||1969|
|Mr. David J. Katzoff||Chief Operating Officer||N/A||N/A||1962|
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
Alzamend Neuro, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.